Clinical Trial Detail

NCT ID NCT03894540
Title A Phase I, Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ipsen
Indications

Advanced Solid Tumor

Therapies

IPN60090

IPN60090 + Pembrolizumab

IPN60090 + Paclitaxel

Age Groups: senior adult

No variant requirements are available.